Acquisition of Elidel completed

Acquisition of Elidel completed

 

Meda's acquisition of global rights for Elidel (pimecrolimus 1% cream) -
announced on 7 April 2011 - has been completed.

About Elidel

Elidel is a patent protected, specialty focused product for the
treatment of atopic dermatitis (AD). Depending on the country, Elidel is
indicated as a second-line therapy for the short and long-term
management of the signs and symptoms of mild to moderate AD in adults
and children two years of age and older.

AD is a chronically relapsing inflammatory skin disease and the skin
barrier plays an essential role in protection against AD flares. Elidel
is the first non-steroidal topical cream treatment specifically
developed for the treatment of AD. To date, Elidel has been studied in
more than 60,000 patients. Elidel is approved and sold in more than 90
countries worldwide.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878